Lantern Total Assets from 2010 to 2025
| LTRN Stock | USD 3.82 0.10 2.69% |
Total Assets | First Reported 2019-12-31 | Previous Quarter 35.6 M | Current Value 30.3 M | Quarterly Volatility 25 M |
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 211.1 K, Interest Expense of 246.8 K or Selling General Administrative of 4.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.07. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
Lantern | Total Assets |
Latest Lantern Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of Lantern Pharma over the last few years. Total assets refers to the total amount of Lantern Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lantern Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Lantern Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 43.65 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Lantern Total Assets Regression Statistics
| Arithmetic Mean | 18,055,867 | |
| Geometric Mean | 2,692,668 | |
| Coefficient Of Variation | 142.17 | |
| Mean Deviation | 21,884,702 | |
| Median | 449,831 | |
| Standard Deviation | 25,669,543 | |
| Sample Variance | 658.9T | |
| Range | 73.5M | |
| R-Value | 0.76 | |
| Mean Square Error | 293.1T | |
| R-Squared | 0.58 | |
| Significance | 0.0006 | |
| Slope | 4,123,460 | |
| Total Sum of Squares | 9883.9T |
Lantern Total Assets History
Other Fundumenentals of Lantern Pharma
Lantern Pharma Total Assets component correlations
Click cells to compare fundamentals
About Lantern Pharma Financial Statements
Lantern Pharma investors utilize fundamental indicators, such as Total Assets, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 50.2 M | 36.4 M |
Check out the analysis of Lantern Pharma Correlation against competitors. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.